Novartis Investigative Site

Grand Rapids, Michigan 49548

0 studies enrolling now · 9 studies all time

What they study most

Age-related Macular Degeneration, Choroidal Neovascularization, Geographic Atrophy, Macular Degeneration, Non-Hodgkin's Lymphoma, Pseudomonas Aeruginosa in Cystic Fibrosis, Relapsing Forms of Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis (RRMS), Schizophrenia

Studies at this site

• Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs — Completed
• Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD) — Completed
• Study of Efficacy of PEAR-004 in Schizophrenia — Completed
• Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis — Completed
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone — Stopped early
• Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy — Stopped early
• Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis — Completed
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization — Completed